Full Year 2025 Results Key Financial Results Revenue: US$292.5m (down 3.8% from FY ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

AngioDynamics expects full-year results to range from a loss of 35 cents per share to a loss of 25 cents per share, with revenue in the range of $305 million to $310 million. AngioDynamics shares have ...

Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at AngioDynamics (ANGO), which currently has a Momentum Style Score of B. We also ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment ...

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and ...